| 1448 |
National Cancer Institute |
Html |
en |
Bladder and Other Urothelial Cancers Screening (PDQ®)–Health Professional Version |
Expert-reviewed information summary about tests used to detect or screen for bladder cancer. |
| bladder cancers | 0.459113 |
| individual developing bladder | 0.462762 |
| bladder cancer patients | 0.501836 |
| Cancer Statistics Review | 0.390961 |
| transitional cell carcinoma | 0.372436 |
| American Cancer Society | 0.389675 |
| bladder cancer | 0.911425 |
| Bladder histological changes | 0.431525 |
| bladder cancer outcome | 0.469139 |
| bladder cancer cases | 0.467655 |
| Malignant bladder tumors | 0.429947 |
| bladder neoplasms | 0.417201 |
| bladder tumours | 0.413309 |
| repetitive hematuria screening | 0.375531 |
| bladder cancer risk | 0.493294 |
| bladder tumors | 0.476533 |
| superficial bladder cancer | 0.470192 |
| hematuria screening studies | 0.380947 |
| bladder toxicity | 0.421878 |
| Natl Cancer Inst | 0.460204 |
| newly diagnosed bladder | 0.471386 |
| Bladder Cancer Group | 0.465328 |
| metastatic bladder cancer | 0.508614 |
| neuropathic bladder | 0.420139 |
| et al. | 0.424244 |
|
| SEER Cancer Statistics | 0.388904 |
| bladder carcinogenesis | 0.425543 |
| bladder wall | 0.415168 |
| bladder cancer mortality | 0.489217 |
| bladder tumor antigen | 0.4299 |
| bladder cancer. | 0.44027 |
| urothelial bladder cancer | 0.487451 |
| Cancer Epidemiol Biomarkers | 0.435283 |
| urothelial cancer | 0.372416 |
| smoking related bladder | 0.437945 |
| PUBMED Abstract | 0.468199 |
| hematuria home screening | 0.413339 |
| bladder cancer case-fatality | 0.488876 |
| invasive bladder cancer | 0.504621 |
| Superficial bladder tumor | 0.43348 |
| National Cancer Institute | 0.389198 |
| Bladder cancer incidence | 0.470999 |
| bladder malignancies | 0.448894 |
| Epidemiol Biomarkers Prev | 0.405245 |
| bladder tumor incidence | 0.430849 |
| Bladder cancer screening | 0.490371 |
| Abstract | 0.469966 |
| recurrent bladder tumors | 0.444789 |
| urinary bladder cancer | 0.487624 |
|
CLICK HERE |
| 1526 |
National Cancer Institute |
Html |
en |
Nasopharyngeal Cancer Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of nasopharyngeal cancer. |
| clinical trial | 0.341084 |
| treatment | 0.278725 |
| clinical trial search | 0.201632 |
| cancer clinical trials | 0.224875 |
| lymph nodes | 0.503913 |
| radiation therapy | 0.653094 |
|
| National Cancer Institute | 0.229813 |
| cancer | 0.952582 |
| nasopharyngeal cancer | 0.779979 |
| clinical trials | 0.675026 |
| affected lymph nodes | 0.35443 |
|
CLICK HERE |
| 1692 |
National Cancer Institute |
Html |
en |
Prostate Cancer, Nutrition, and Dietary Supplements (PDQ®)–Patient Version |
Expert-reviewed information summary about the use of nutrition and dietary supplements for reducing the risk of developing prostate cancer or for treating prostate cancer. |
| advanced prostate cancer | 0.462339 |
| anticancer effects | 0.463801 |
| clinical trial search | 0.473734 |
| green tea extract | 0.477186 |
| medical condition | 0.458517 |
| PSA levels | 0.542556 |
| clinical trials | 0.664244 |
| hormone-refractory prostate cancer | 0.474056 |
| U.S. Food | 0.502589 |
| early prostate cancer | 0.465338 |
| placebo | 0.450024 |
| laboratory studies | 0.464618 |
| prostate cancer cells | 0.484177 |
| prostate cancer risk | 0.582265 |
| food products | 0.450637 |
| prostate specific antigen | 0.47312 |
| prostate cancer patients | 0.605367 |
| population studies | 0.543492 |
| Prostate cancer deaths | 0.462733 |
| effects | 0.499767 |
| prostate cancer rates | 0.456143 |
| lycopene | 0.466211 |
| prostate cancers | 0.457956 |
| treatment | 0.466735 |
| study | 0.482571 |
|
| prostate cancer prevention | 0.485364 |
| androgen-independent prostate cancer | 0.473958 |
| tumor cells | 0.455948 |
| United States | 0.574219 |
| recurrent prostate cancer | 0.457873 |
| Drug Administration | 0.504644 |
| NCI-supported cancer | 0.451146 |
| products | 0.463319 |
| high-grade prostate cancer | 0.459874 |
| selenium | 0.479361 |
| dietary supplements | 0.709022 |
| studies | 0.641892 |
| general information | 0.454636 |
| green tea | 0.628302 |
| animal studies | 0.638323 |
| professional version | 0.461561 |
| low-grade prostate cancer | 0.456901 |
| label claims | 0.456268 |
| mixed results | 0.4651 |
| prostate cancer | 0.981204 |
| cancer clinical trials | 0.48181 |
| selenium supplements | 0.463263 |
| aggressive prostate cancer | 0.460411 |
| Laboratory/Animal/Preclinical Studies section | 0.507788 |
|
CLICK HERE |
| 1848 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de piel (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de piel. |
| Compton CC | 0.427006 |
| ángulo nariz-mejilla | 0.312075 |
| Cutaneous squamous | 0.410175 |
| criocirugÃa frente | 0.310658 |
| skin cancers | 0.337834 |
| señalización tipo erizo | 0.316126 |
| basal-cell carcinoma | 0.31436 |
| American Cancer Society | 0.31065 |
| Casciato DA | 0.3104 |
| 7th ed | 0.425796 |
| Dermatol Surg Oncol | 0.322688 |
| TFD frente | 0.31135 |
| cutaneous carcinomas | 0.448478 |
| Mohs surgery is | 0.310939 |
| Plast Reconstr Surg | 0.318551 |
| carcinomas cutáneos | 0.316845 |
| Estados Unidos | 0.319384 |
| Natl Cancer Inst | 0.311163 |
| human papillomavirus infection | 0.320874 |
| CCE invasor | 0.312649 |
| Euros frente | 0.310849 |
| N2a Metástasis | 0.310265 |
| cell carcinomas | 0.926899 |
| escisión frente | 0.315633 |
| Arch Dermatol | 0.342458 |
|
| Carcinoma apocrino | 0.319357 |
| uncomplicated basal cell | 0.313087 |
| Invest Dermatol | 0.31893 |
| Mohs micrographic surgery | 0.311178 |
| micosis fungoide | 0.313548 |
| Cancer Staging Manual | 0.594205 |
| recidivas locales | 0.316877 |
| PDQ Tratamiento | 0.321192 |
| New York | 0.409746 |
| Day CL Jr | 0.315276 |
| clasificación tnm | 0.310941 |
| células escamosas cutáneos | 0.311636 |
| Dermatol Surg | 0.324225 |
| Byrd DR | 0.419056 |
| T2b Tumor | 0.314992 |
| Karagas MR | 0.311264 |
| basal cell carcinomas | 0.750035 |
| American Joint Committee | 0.344157 |
| párpadoa aReproducción | 0.326393 |
| tumor fotosensibilizadores | 0.313881 |
| Tis Carcinoma | 0.334823 |
| Carcinoma arising | 0.318249 |
| AJCC Cancer Staging | 0.604512 |
| Edge SB | 0.427178 |
|
CLICK HERE |
| 1878 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de seno (mama) masculino (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de seno (mama) masculino. |
| Giordano SH | 0.546628 |
| Italian Oncology Group | 0.503266 |
| aromatase inhibitors | 0.504835 |
| Sin embargo | 0.505052 |
| accessed october | 0.502081 |
| American Cancer Society | 0.521913 |
| sumario tratamiento | 0.50893 |
| PALB2 mutations | 0.502161 |
| Terapia sistémica preoperatoria | 0.504717 |
| Instituto Nacional | 0.507139 |
| Vlamis V | 0.505558 |
| male breast | 0.773618 |
| DeVita VT Jr | 0.502939 |
| Wong GY | 0.505822 |
| population-based study | 0.506079 |
| carcinoma lobulillar | 0.502812 |
| hereditary male breast | 0.514858 |
| estadificación tnm | 0.502579 |
| Buzdar AU | 0.511225 |
| breast carcinoma | 0.529746 |
| German Breast Group | 0.523976 |
| Adjuvant therapy with | 0.503518 |
| male breast carcinoma | 0.523697 |
| Cancer Facts | 0.511201 |
| parientes mujeres | 0.50281 |
|
| tumores pten | 0.506695 |
| Cancer Res Treat | 0.581998 |
| National Cancer Institute | 0.509524 |
| or without gonadotropin-releasing | 0.502999 |
| PDQ Tratamiento | 0.571327 |
| versus ia | 0.508803 |
| Hortobagyi GN | 0.519998 |
| Intern Med | 0.505973 |
| cancer susceptibility | 0.510328 |
| cases from | 0.502419 |
| metastatic breast | 0.510618 |
| Clin Oncol | 0.505305 |
| IA vs | 0.504284 |
| Physician Data Query | 0.502682 |
| breast cancer | 0.966614 |
| estadios tnm | 0.502728 |
| Oncology Group Phase | 0.503374 |
| Aromatase inhibitors with | 0.503642 |
| PDQ Sofocos | 0.507587 |
| Current management | 0.505493 |
| Oncology Group | 0.504752 |
| Borgen PI | 0.505535 |
| Hormonal treatment | 0.502423 |
| Breast Cancer Res | 0.608904 |
|
CLICK HERE |
| 2045 |
National Cancer Institute |
Html |
es |
Exámenes de detección del cáncer de ovario, de trompas de Falopio y primario de peritoneo (PDQ®)–Versión para profesionales de salud |
Sumario de información revisada por expertos sobre pruebas que se usan para detectar el cáncer de ovario, de trompas de Falopio y primario de peritoneo. |
| Obstet Gynecol | 0.429928 |
| United Kingdom Collaborative | 0.409268 |
| Bast RC Jr | 0.42202 |
| Jacobs IJ | 0.404314 |
| ensayo ca-125 | 0.406196 |
| randomised controlled | 0.404882 |
| ovarian cancer algorithm | 0.442917 |
| término cáncer | 0.410224 |
| Longitudinal screening algorithm | 0.406983 |
| American Cancer Society | 0.41643 |
| gynecologic cancers | 0.414338 |
| Cancer Screening Randomized | 0.428277 |
| ensayo plco | 0.448316 |
| Kingdom Collaborative Trial | 0.414212 |
| ecografÃa transvaginal | 0.498268 |
| serum ca-125 levels | 0.405779 |
| Instituto Nacional | 0.405706 |
| screening trial specimens | 0.40956 |
| ovarian cancer | 0.962069 |
| grupo control | 0.404575 |
| PDQ Exámenes | 0.408591 |
| uk collaborative trial | 0.420355 |
| ovarian carcinoma | 0.410371 |
| Estados Unidos | 0.412447 |
| Natl Cancer Inst | 0.419302 |
|
| Randomized Controlled Trial | 0.413244 |
| Partridge E | 0.417834 |
| CA-125 velocity | 0.404292 |
| PDQ Prevención | 0.409813 |
| Gynecol Oncol | 0.414371 |
| detección simultáneos | 0.410338 |
| SEER Cancer Statistics | 0.408582 |
| using transvaginal sonography | 0.404548 |
| cohort study | 0.404541 |
| marcador sérico ca-125 | 0.406906 |
| Cancer Facts | 0.408569 |
| controlled trial | 0.421989 |
| National Cancer Institute | 0.418053 |
| Gynecologic Cancer Predisposition | 0.409737 |
| collaborative trial | 0.433295 |
| Shizuoka Cancer Registry | 0.409677 |
| PDQ Genetics | 0.404479 |
| Gynecol Cancer | 0.409511 |
| cancer screening trial | 0.473823 |
| PLCO trial with | 0.406621 |
| Screening Randomized Controlled | 0.416835 |
| Buys SS | 0.413143 |
| ovarian cancer screening | 0.679966 |
| mujeres morirán | 0.405822 |
|
CLICK HERE |
| 3422 |
National Cancer Institute |
Html |
es |
Reconstrucción del seno después de una mastectomía |
Hoja informativa que describe la reconstrucción del seno (mama) después de una mastectomía. Contiene información sobre las opciones quirúrgicas, los cuidados de seguimiento y los exámenes de detección del cáncer de seno después de la reconstrucción. |
| cirugÃa abdominal | 0.39888 |
| ley whcra | 0.35286 |
| Nipple-sparing mastectomy—is it | 0.332063 |
| Cordeiro PG | 0.320216 |
| colgajo siep | 0.393996 |
| Colgajo TRAM | 0.39889 |
| suficiente piel | 0.387487 |
| largo plazo | 0.34858 |
| large cell lymphoma | 0.395571 |
| reconstruction following surgery | 0.356853 |
| Reconstructive Surgery | 0.417753 |
| Colgajo SGAP | 0.397479 |
| Colgajo PAP | 0.399861 |
| Colgajo Latissimus | 0.401399 |
| PubMed Abstract | 0.945047 |
| Colgajo TUG | 0.398937 |
| colgajo diep | 0.587224 |
| Surgical Oncology Clinics | 0.338406 |
| CirugÃa oncoplástica. | 0.339864 |
| La Cruz L | 0.324776 |
| NCI titulada MamografÃas | 0.32023 |
| breast reconstruction | 0.705756 |
| colgajo igap | 0.469394 |
| pequeños trozos | 0.3196 |
| suficiente tejido | 0.3777 |
|
| colgajos ld | 0.342761 |
| Colgajo SIEA | 0.398955 |
| Da Lio A | 0.329732 |
| implantes de solución | 0.348682 |
| reconstruction after surgery | 0.366752 |
| therapy implications following | 0.337385 |
| suficiente volumen | 0.324436 |
| reconstrucción retardada | 0.559365 |
| Breast reconstruction after | 0.445489 |
| reconstruction after mastectomy | 0.350953 |
| Petit JY | 0.31974 |
| Breast Disease | 0.377661 |
| Cancer Rights Act | 0.334748 |
| Reviews Clinical Oncology | 0.3359 |
| oncoplastic breast-conserving surgery | 0.341614 |
| Total skin sparing | 0.332343 |
| técnica llamada | 0.357673 |
| sensibilidad conforme crecen y | 0.339464 |
| anaplastic large cell | 0.394345 |
| New England Journal | 0.330568 |
| ¿qué tipo | 0.325566 |
| physical therapy | 0.407423 |
| systematic reviews | 0.354768 |
| Surgical Oncology | 0.355698 |
|
CLICK HERE |
| 16776 |
National Cancer Institute |
Html |
es |
Cancell/Cantron/Protocel (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos sobre el uso de Cancell/Cantron/Protocel como tratamiento para personas con cáncer. Nota: La información contenida en este sumario ya no se actualiza y se ofrece solo con fines de consulta. |
| Questionable methods | 0.583285 |
| NCI Tumor Cell | 0.253187 |
| Alternative Cancer Treatment | 0.949939 |
| Cancell Alternative Cancer | 0.909029 |
| physiological consequences | 0.221271 |
| Dills WL Jr | 0.236274 |
| Pedersen PL | 0.220212 |
| James V | 0.220328 |
| CA Cancer | 0.715566 |
| Instituto Nacional | 0.460523 |
| Tumor Cell Line | 0.306478 |
| Livingston-Wheeler therapy | 0.223682 |
| nombre cancell | 0.23058 |
| Estados Unidos | 0.337461 |
| mutational events that | 0.237295 |
| Cassileth BR | 0.27252 |
| Complementary Therapies | 0.275875 |
| tumour glycolysis | 0.221381 |
| Oncogenic alterations | 0.222154 |
| NCI-60 DTP Human | 0.237422 |
| Eastern District | 0.221187 |
| WW Norton | 0.271304 |
| Bioenerg Biomembr | 0.223121 |
| peso promedio | 0.220355 |
| District Court | 0.221556 |
|
| Alternative Medicine Handbook | 0.357021 |
| Edmund J | 0.22088 |
| United States | 0.221128 |
| bacteria p | 0.221477 |
| Semenza GL | 0.221681 |
| diabetes mellitus | 0.223111 |
| llamó entelev | 0.224971 |
| tipo cancell | 0.228779 |
| vÃa oral | 0.22206 |
| Winter Works | 0.543066 |
| Trends Biochem Sci | 0.237977 |
| critical role | 0.221303 |
| Dang CV | 0.220582 |
| Mathupala SP | 0.220471 |
| National Cancer Institute | 0.327107 |
| Aberrant glycolytic metabolism | 0.237912 |
| Permanent Injunction | 0.223017 |
| New York | 0.262714 |
| accessed april | 0.557875 |
| Cell Line Screen | 0.307726 |
| Physician Data Query | 0.23188 |
| Complete Reference Guide | 0.33124 |
| células primitivas resultantes | 0.275971 |
| Máxima concentración | 0.230742 |
|
CLICK HERE |
| 16843 |
National Cancer Institute |
Html |
en |
Massachusetts General Hospital and Harvard Univeristy — Imaging of Nanotherapeutic Drug Action |
In vivo imaging analyses of therapeutic nanoparticles (TNP), addressing key questions on nanoparticle distribution (pharmacokinetics, PK) and cellular response (pharmacodynamics, PD). |
| nanoparticle distribution | 0.841511 |
| enhanced MR imaging | 0.924949 |
| biological understanding | 0.766676 |
| Alliance members | 0.763245 |
| M.D. | 0.664358 |
| vivo imaging analyses | 0.983793 |
| Claudio Vinegoni | 0.829503 |
| Cesar Castro | 0.816804 |
| cancer cells | 0.772225 |
| NCI Alliance | 0.790962 |
| Ph.D | 0.666483 |
| project team | 0.768015 |
| considerable proportion | 0.780069 |
| clinical data | 0.766134 |
| recent developments | 0.775301 |
| multimodality imaging | 0.800032 |
| larger number | 0.783733 |
| affinity ligands | 0.782978 |
| cancer nanotechnology questions | 0.94124 |
| Ralph Weissleder | 0.799712 |
| TNP | 0.654222 |
| free survival | 0.789955 |
| vivo imaging technologies | 0.994916 |
| nano-encapsulated chemotherapeutics | 0.788661 |
|
| recent feasibility studies | 0.924078 |
| lower toxicity | 0.785357 |
| cancer members | 0.792525 |
| molecular diagnostics | 0.779336 |
| new strategy | 0.77113 |
| following questions | 0.766532 |
| new constructs | 0.797665 |
| new biological insight | 0.926895 |
| vivo setting | 0.83945 |
| tumoral accumulation | 0.816621 |
| temporal heterogeneity | 0.803444 |
| key questions | 0.775023 |
| future interactions | 0.756886 |
| efficacy | 0.740414 |
| tumoral myeloid cells | 0.915593 |
| Principal Investigators | 0.797013 |
| tumor cell accumulation | 0.959124 |
| therapeutic nanoparticles | 0.774355 |
| molecular / cell | 0.763144 |
| occasionally improved progression | 0.958519 |
| Mikael Pittet | 0.837942 |
| cancer biology | 0.77172 |
| Alliance projects | 0.764335 |
|
CLICK HERE |
| 17186 |
National Cancer Institute |
Html |
en |
TMIST (Tomosynthesis Mammographic Imaging Screening Trial) |
TMIST is a randomized breast screening trial that compares two Food and Drug Administration (FDA)-approved types of digital mammography, standard digital mammography (2-D) with a newer technology called tomosynthesis mammography (3-D). |
| routine screening mammogram | 0.506393 |
| entire study group | 0.421549 |
| tomosynthesis mammography | 0.449515 |
| health plans | 0.41281 |
| 3-D mammography | 0.660743 |
| trial | 0.465454 |
| breast cancer status | 0.514295 |
| standard digital mammography | 0.512193 |
| 3-D mammogram | 0.462356 |
| women ages | 0.504522 |
| following factors | 0.42666 |
| breast biopsies | 0.439927 |
| fewer false-positive test | 0.416422 |
| researchers | 0.394009 |
| 2-D screening mammograms | 0.502737 |
| mammography clinics | 0.435449 |
| aggressive breast cancers | 0.493477 |
| ECOG-ACRIN Cancer Research | 0.42875 |
| 2-D mammography | 0.505053 |
| 3-D mammograms | 0.447984 |
| hormone replacement therapy | 0.765582 |
| randomized breast | 0.472367 |
| personal risk factors | 0.42803 |
| primary care doctors | 0.417168 |
| women | 0.662197 |
|
| risk changes | 0.412147 |
| fewer harder-to-treat cancers | 0.422139 |
| study | 0.460399 |
| best ways | 0.450667 |
| mammograms | 0.529145 |
| age group | 0.430585 |
| certain groups | 0.456471 |
| breast cancers | 0.534289 |
| dense breasts | 0.527755 |
| complete cost | 0.412269 |
| premenopausal women | 0.386263 |
| routine mammogram | 0.443785 |
| mammogram | 0.569066 |
| 3-D mammography machines | 0.510266 |
| 3-D mammography images | 0.549905 |
| breast cancer screening | 0.609852 |
| newly diagnosed breast | 0.491574 |
| nearby lymph node | 0.415404 |
| breast cancer | 0.940336 |
| trial record | 0.381013 |
| tissue samples | 0.430822 |
| genetic changes | 0.428717 |
| Women’s health | 0.38389 |
| family history | 0.510755 |
|
CLICK HERE |